|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuczynski EA, Sargent DJ, Grothey A and
Kerbel RS: Drug rechallenge and treatment beyond progression -
implications for drug resistance. Nat Rev Clin Oncol. 10:571–587.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parton RG and Simons K: The multiple faces
of caveolae. Nat Rev Mol Cell Biol. 8:185–194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang B, Peng F, Wu D, Ingram AJ, Gao B
and Krepinsky JC: Caveolin-1 phosphorylation is required for
stretch-induced EGFR and Akt activation in mesangial cells. Cell
Signal. 19:1690–1700. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park JH and Han HJ: Caveolin-1 plays
important role in EGF-induced migration and proliferation of mouse
embryonic stem cells: involvement of PI3K/Akt and ERK. Am J Physiol
Cell Physiol. 297:C935–C944. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Quest AF, Gutierrez-Pajares JL and Torres
VA: Caveolin-1: An ambiguous partner in cell signalling and cancer.
J Cell Mol Med. 12:1130–1150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen HL, Fan LF, Gao J, Ouyang JP and
Zhang YX: Differential expression and function of the caveolin-1
gene in non-small cell lung carcinoma. Oncol Rep. 25:359–366. 2011.
View Article : Google Scholar
|
|
8
|
Park J, Bae E, Lee C, Yoon SS, Chae YS,
Ahn KS and Won NH: RNA interference-directed caveolin-1 knockdown
sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and
reduces lung metastasis. Tumor Biol. 31:643–650. 2010. View Article : Google Scholar
|
|
9
|
Rödel F, Capalbo G, Rödel C and Weiss C:
Caveolin-1 as a prognostic marker for local control after
preoperative chemoradiation therapy in rectal cancer. Int J Radiat
Oncol Biol Phys. 73:846–852. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hehlgans S, Eke I, Storch K, Haase M,
Baretton GB and Cordes N: Caveolin-1 mediated radioresistance of 3D
grown pancreatic cancer cells. Radiother Oncol. 92:362–370. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burrows AD, Restall C, Sloan EK and
Anderson RL: The contribution of stromal caveolin-1 to breast
cancer metastasis. Cancer Res. 72:1486. 2012. View Article : Google Scholar
|
|
12
|
Rao X, Evans J, Chae H, Pilrose J, Kim S,
Yan P, Huang RL, Lai HC, Lin H, Liu Y, et al: CpG island shore
methylation regulates caveolin-1 expression in breast cancer.
Oncogene. 32:4519–4528. 2013. View Article : Google Scholar :
|
|
13
|
Xu J, Agyemang S, Qin Y, Aysola K, Giles
M, Oprea G, O'Regan RM, Partridge EE, Harris-Hooker S, Rice VM, et
al: A novel pathway that links Caveolin-1 down-regulation to BRCA1
dysfunction in serous epithelial ovarian cancer cells. Enliven
Chall Cancer Detect Ther. 1:pii0042014.
|
|
14
|
Goetz JG, Lajoie P, Wiseman SM and Nabi
IR: Caveolin-1 in tumor progression: The good, the bad and the
ugly. Cancer Metastasis Rev. 27:715–735. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai C and Chen J: Overexpression of
caveolin-1 induces alteration of multidrug resistance in Hs578T
breast adenocarcinoma cells. Int J Cancer. 111:522–529. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Selga E, Morales C, Noe V, Peinado MA and
Ciudad CJ: Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha
on resistance to methotrexate in human HT29 colon cancer cells. BMC
Med Genomics. 1:1755–8794. 2008. View Article : Google Scholar
|
|
17
|
Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH
and Yang PC: Caveolin-1 expression is significantly associated with
drug resistance and poor prognosis in advanced non-small cell lung
cancer patients treated with gemcitabine-based chemotherapy. Lung
Cancer. 59:105–110. 2008. View Article : Google Scholar
|
|
18
|
Wiechen K, Diatchenko L, Agoulnik A,
Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M,
Schäfer R, et al: Caveolin-1 is down-regulated in human ovarian
carcinoma and acts as a candidate tumor suppressor gene. Am J
Pathol. 159:1635–1643. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu ZJ, Xiao M, Balint K, Smalley KS,
Brafford P, Qiu R, Pinnix CC, Li X and Herlyn M: Notch1 signaling
promotes primary melanoma progression by activating
mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt
pathways and up-regulating N-cadherin expression. Cancer Res.
66:4182–4190. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aoki K, Ogawa T, Ito Y and Nakashima S:
Cisplatin activates survival signals in UM-SCC-23 squamous cell
carcinoma and these signal pathways are amplified in
cisplatin-resistant squamous cell carcinoma. Oncol Rep. 11:375–379.
2004.PubMed/NCBI
|
|
21
|
Wang Z, Li Y, Banerjee S, Kong D, Ahmad A,
Nogueira V, Hay N and Sarkar FH: Down-regulation of Notch-1 and
Jagged-1 inhibits prostate cancer cell growth, migration and
invasion, and induces apoptosis via inactivation of Akt, mTOR, and
NF-kappaB signaling pathways. J Cell Biochem. 109:726–736.
2010.PubMed/NCBI
|
|
22
|
Romashkova JA and Makarov SS: NF-κB is a
target of AKT in anti-apoptotic PDGF signalling. Nature. 401:86–90.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou W, Fu XQ, Zhang LL, Zhang J, Huang X,
Lu XH, Shen L, Liu BN, Liu J, Luo HS, et al: The
AKT1/NF-kappaB/Notch1/PTEN axis has an important role in
chemoresistance of gastric cancer cells. Cell Death Dis.
4:e8472013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu H, Bhaijee F, Ishaq N, Pepper DJ,
Backus K, Brown AS, Zhou X and Miele L: Correlation of Notch1, pAKT
and nuclear NF-κB expression in triple negative breast cancer. Am J
Cancer Res. 3:2302013.
|
|
25
|
Wang S, Kan Q, Sun Y, Han R, Zhang G, Peng
T and Jia Y: Caveolin-1 regulates neural differentiation of rat
bone mesen-chymal stem cells into neurons by modulating Notch
signaling. Int J Dev Neurosci. 31:30–35. 2013. View Article : Google Scholar
|
|
26
|
Chanvorachote P, Chunhacha P and
Pongrakhananon V: Caveolin-1 induces lamellipodia formation via an
Akt-dependent pathway. Cancer Cell Int. 14:1475–2867. 2014.
View Article : Google Scholar
|
|
27
|
Hada N, Okayasu M, Ito J, Nakayachi M,
Hayashida C, Kaneda T, Uchida N, Muramatsu T, Koike C, Masuhara M,
et al: Receptor activator of NF-κB ligand-dependent expression of
caveolin-1 in osteoclast precursors, and high dependency of
osteoclastogenesis on exogenous lipoprotein. Bone. 50:226–236.
2012. View Article : Google Scholar
|
|
28
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rebucci M and Michiels C: Molecular
aspects of cancer cell resistance to chemotherapy. Biochem
Pharmacol. 85:1219–1226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Groeneweg JW, Foster R, Growdon WB,
Verheijen RH and Rueda BR: Notch signaling in serous ovarian
cancer. J Ovarian Res. 7:952014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu L-Z, Zhou X-D, Qian G, Shi X, Fang J
and Jiang B-H: AKT1 amplification regulates cisplatin resistance in
human lung cancer cells through the mammalian target of
rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhong H, Voll RE and Ghosh S:
Phosphorylation of NF-κB p65 by PKA stimulates transcriptional
activity by promoting a novel bivalent interaction with the
coactivator CBP/p300. Mol Cell. 1:661–671. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bélanger MM, Roussel E and Couet J:
Caveolin-1 is down-regulated in human lung carcinoma and acts as a
candidate tumor suppressor gene. Chest. 125(5 Suppl): 106S2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Razani B, Schlegel A, Liu J and Lisanti M:
Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans.
29:494–499. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huertas-Martínez J, Barrau I,
Sainz-Jaspeado M, Lagares-Tena L, Mateo-Lozano S, Mora J, Roma J,
Gallego S, Moran S, Esteller M, et al: Caveolin-1 acts as a tumor
suppressor promoting muscular differentiation in alveolar
rhabdomyosarcomas. Cancer Res. 73:38272013. View Article : Google Scholar
|
|
36
|
Wikman H, Kettunen E, Seppänen JK,
Karjalainen A, Hollmén J, Anttila S and Knuutila S: Identification
of differentially expressed genes in pulmonary adenocarcinoma by
using cDNA array. Oncogene. 21:5804–5813. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee SW, Reimer CL, Oh P, Campbell DB and
Schnitzer JE: Tumor cell growth inhibition by caveolin
re-expression in human breast cancer cells. Oncogene. 16:1391–1397.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bender FC, Reymond MA, Bron C and Quest
AF: Caveolin-1 levels are down-regulated in human colon tumors, and
ectopic expression of caveolin-1 in colon carcinoma cell lines
reduces cell tumorigenicity. Cancer Res. 60:5870–5878.
2000.PubMed/NCBI
|
|
39
|
Cantiani L, Manara MC, Zucchini C, De
Sanctis P, Zuntini M, Valvassori L, Serra M, Olivero M, Di Renzo
MF, Colombo MP, et al: Caveolin-1 reduces osteosarcoma metastases
by inhibiting c-Src activity and met signaling. Cancer Res.
67:7675–7685. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tang Y, Zeng X, He F, Liao Y, Qian N and
Toi M: Caveolin-1 is related to invasion, survival, and poor
prognosis in hepatocellular cancer. Med Oncol. 29:977–984. 2012.
View Article : Google Scholar
|
|
41
|
Wang R, He W, Li Z, Chang W, Xin Y and
Huang T: Caveolin-1 functions as a key regulator of
17β-estradiol-mediated autophagy and apoptosis in BT474 breast
cancer cells. Int J Mol Med. 34:822–827. 2014.PubMed/NCBI
|
|
42
|
Karam JA, Lotan Y, Roehrborn CG, Ashfaq R,
Karakiewicz PI and Shariat SF: Caveolin-1 overexpression is
associated with aggressive prostate cancer recurrence. Prostate.
67:614–622. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Florea A-M and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers (Basel). 3:1351–1371.
2011. View Article : Google Scholar
|
|
44
|
Cole SP, Bhardwaj G, Gerlach JH, Mackie
JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and
Deeley RG: Overexpression of a transporter gene in a
multidrug-resistant human lung cancer cell line. Science.
258:1650–1654. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stordal B, Hamon M, McEneaney V, Roche S,
Gillet JP, O'Leary JJ, Gottesman M and Clynes M: Resistance to
paclitaxel in a cisplatin-resistant ovarian cancer cell line is
mediated by P-glycoprotein. PLoS One. 7:e407172012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bourhis J, Goldstein LJ, Riou G, Pastan I,
Gottesman MM and Bénard J: Expression of a human multidrug
resistance gene in ovarian carcinomas. Cancer Res. 49:5062–5065.
1989.PubMed/NCBI
|
|
47
|
van der Zee AG, Hollema H, Suurmeijer AJ,
Krans M, Sluiter WJ, Willemse PH, Aalders JG and de Vries EG: Value
of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53
as prognostic factors in ovarian carcinomas. J Clin Oncol.
13:70–78. 1995.PubMed/NCBI
|
|
48
|
Bray SJ: Notch signalling: a simple
pathway becomes complex. Nat Rev Mol Cell Biol. 7:678–689. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Perdigoto CN and Bardin AJ: Sending the
right signal: Notch and stem cells. Biochim Biophys Acta.
1830:2307–2322. 2013. View Article : Google Scholar
|
|
50
|
Hopfer O, Zwahlen D, Fey M and Aebi S: The
Notch pathway in ovarian carcinomas and adenomas. Br J Cancer.
93:709–718. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yanjie J, Jiping S, Yan Z, Xiaofeng Z,
Boai Z and Yajun L: Effects of Notch-1 signalling pathway on
differentiation of marrow mesenchymal stem cells into neurons in
vitro. Neuroreport. 18:1443–1447. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Campos LS, Decker L, Taylor V and Skarnes
W: Notch, epidermal growth factor receptor, and beta1-integrin
pathways are coordinated in neural stem cells. J Biol Chem.
281:5300–5309. 2006. View Article : Google Scholar
|
